The central theme of the Cancer Prevention and Control (CPC) program is to translate its research findings into practice and policy to improve the prevention, detection, treatment, and control of cancer. The CPC program strives to enhance the quality of life of all individuals affected by cancer, including a large African American population served within the MCC catchment area. MCC received distinction as a Minority Based NCI Oncology Research Program Community Site to further advance research in this important area of need. Additionally, CPC clinical trials and much of the program?s basic science research addresses disparities in this population. The CPC program has 36 members representing 12 departments and 4 schools. Currently, the CPC program has a total peer-reviewed cancer-related funding base of approximately $6.5 million in direct costs, of which nearly $2.3 million is from the NCI and over $3 million is from other NIH institutes. During 2011 to 2015, the CPC program had a total of 475 publications, of which 22% were intraprogrammatic and 10% were interprogrammatic. The scientific goals of the program are highlighted by its themes of (1) reducing cancer risk and (2) improving cancer-related care, both of which are tied together by the cross-cutting theme of alleviating disparities. CPC continues to achieve significant impact in these areas as evidenced by the program?s accomplishments of: translating MCC basic science findings into clinical trials for a novel smoking cessation therapy (now in phase IIa clinical trials in collaboration with the University of Pittsburgh Cancer Institute); informing the FDA and WHO tobacco policy on modified-risk tobacco products such as e-cigarettes with CPC?s first multi-PI P50 grant; decreasing cancer risk through obesity control in high-risk populations? adolescents and African Americans; improving cancer screening decision making; enhancing patient and caregiver experience with cancer care; identifying Medicaid and other policy effects on access to care; identifying barriers to African American enrollment in clinical research trials; and developing methods to overcome these barriers. In line with the NCI priority to foster multidisciplinary research, MCC has facilitated cross-cutting collaborations by generating an award program dedicated to CPC interprogrammatic pilot projects, several of which have recently led to large externally-funded grant projects. Value is added by MCC shared resources and CPC-sponsored education and training through monthly seminars, interprogrammatic research retreats, competitive CPC pilot grants, and through support of student and trainee fellowships. In summary, the CPC program is a vital, dynamic, and growing program within MCC, which addresses the unique needs of the MCC catchment area, as well as the nation more generally. The program, with its vibrant research agenda, engaged multidisciplinary membership, and ongoing support from MCC is well poised to continue to build upon the impact of its high-quality basic science, clinical, policy, and outcomes research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-37S3
Application #
9758994
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
37
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Vrzalikova, K; Ibrahim, M; Vockerodt, M et al. (2018) S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. Leukemia 32:214-223
Stockstill, Katherine; Doyle, Timothy M; Yan, Xisheng et al. (2018) Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med 215:1301-1313
Mitrano, Darlene A; Jackson, Kelsey; Finley, Samantha et al. (2018) ?1b-Adrenergic Receptor Localization and Relationship to the D1-Dopamine Receptor in the Rat Nucleus Accumbens. Neuroscience 371:126-137
Ma, Yibao; Temkin, Sarah M; Hawkridge, Adam M et al. (2018) Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett 435:92-100
Anscher, Mitchell S; Chang, Michael G; Moghanaki, Drew et al. (2018) A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin. Am J Clin Oncol 41:544-548
Menezes, Mitchell E; Bhoopathi, Praveen; Pradhan, Anjan K et al. (2018) Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases. Adv Cancer Res 138:143-182
Rodrigues, Collin J; Bobb, Julian A; John, Mallory G et al. (2018) Nucleation and growth of gold nanoparticles initiated by nanosecond and femtosecond laser irradiation of aqueous [AuCl4]. Phys Chem Chem Phys 20:28465-28475
Payne, Kyle K; Aqbi, Hussein F; Butler, Savannah E et al. (2018) Gr1-/low CD11b-/low MHCII+ myeloid cells boost T cell anti-tumor efficacy. J Leukoc Biol 104:1215-1228
Wu, Xiaowei; Guan, Ting; Liu, Dajiang J et al. (2018) ADAPTIVE-WEIGHT BURDEN TEST FOR ASSOCIATIONS BETWEEN QUANTITATIVE TRAITS AND GENOTYPE DATA WITH COMPLEX CORRELATIONS. Ann Appl Stat 12:1558-1582
Chawla, Ayesha T; Cororaton, Agnes D; Idowu, Michael O et al. (2018) An intestinal stem cell niche in Apc mutated neoplasia targetable by CtBP inhibition. Oncotarget 9:32408-32418

Showing the most recent 10 out of 586 publications